Cryoport, Inc.

NasdaqCM:CYRX Lagerbericht

Marktkapitalisierung: US$543.8m

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Cryoport Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Cryoport wird ein jährliches Wachstum der Erträge und Einnahmen um 8.4% bzw. 9.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 17.9% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -3.1% betragen.

Wichtige Informationen

34.5%

Wachstumsrate der Gewinne

36.6%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum16.8%
Wachstumsrate der Einnahmen9.6%
Zukünftige Eigenkapitalrendite-11.8%
Analystenabdeckung

Good

Zuletzt aktualisiert09 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Cryoport Tanks On Chilling Results And Bad Decisions

Mar 14

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Mar 10
Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Jan 15
Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Oct 06
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Jul 23
Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Jul 12
Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Jun 13
Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 06
Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Nov 07
Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Sep 23
Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Cryoport: A Rare Investing Opportunity

Sep 22

Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services

Sep 08

Cryoport: Rapid Growth Is Great, But Shares Look Overpriced

Jul 30

Cryoport: To Resume Aggressive Growth

May 11

Cryoport: An Industry Leader Basking In Industry Tailwinds

Apr 15

Cryoport: Risky Investment With Upside Potential

Apr 01

Cryoport: More Growth Going Into New Year 2022

Dec 29

Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

Dec 05
Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

What Is Cryoport, Inc.'s (NASDAQ:CYRX) Share Price Doing?

Nov 09
What Is Cryoport, Inc.'s (NASDAQ:CYRX) Share Price Doing?

Is Cryoport (NASDAQ:CYRX) Using Too Much Debt?

Oct 17
Is Cryoport (NASDAQ:CYRX) Using Too Much Debt?

Cryoport: The Golden Stock

Oct 08

Cryoport: Unfairly Punished, Valuation Update Shows 45% Upside

Oct 01

Cryoport: Best Price-Positioned Medical Services Stock, As Seen By Market-Makers

Jul 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CYRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/2026295-5213265
12/31/2025266-55-1259
12/31/2024243-69-45-2210
3/31/2024225-121-46-7N/A
12/31/2023233-108-46-1N/A
9/30/2023236-55-410N/A
6/30/2023241-47-323N/A
3/31/2023248-38-290N/A
12/31/2022237-45-26-2N/A
9/30/2022233-296-27-3N/A
6/30/2022230-297-235N/A
3/31/2022222-293-1215N/A
12/31/2021223-284-178N/A
9/30/2021215-76-25-4N/A
6/30/2021169-78-32-18N/A
3/31/2021122-77-34-22N/A
12/31/202079-75-25-15N/A
9/30/202040-22-11-4N/A
6/30/202038-23-60N/A
3/31/202037-20-50N/A
12/31/201934-18-7-1N/A
9/30/201930-20-8-2N/A
6/30/201926-9-7-2N/A
3/31/201922-9-6-2N/A
12/31/201820-10-6-3N/A
9/30/201817-10-7-4N/A
6/30/201815-9-6-5N/A
3/31/201813-9-5-4N/A
12/31/201712-8N/A-4N/A
9/30/201711-10N/A-3N/A
6/30/201710-10N/A-4N/A
3/31/20179-12N/A-5N/A
12/31/20168-13N/A-6N/A
9/30/20167-12N/A-6N/A
6/30/20166-12N/A-6N/A
3/31/20166-15N/A-6N/A
12/31/20156-16N/A-6N/A
9/30/20155-15N/A-5N/A
6/30/20154-16N/A-5N/A
3/31/20154-12N/A-4N/A
12/31/20144-10N/A-4N/A
9/30/20143-10N/A-4N/A
6/30/20143-21N/A-4N/A
3/31/20143-20N/A-4N/A
12/31/20132-20N/A-4N/A
9/30/20132-20N/A-4N/A
6/30/20131-6N/A-5N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CYRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CYRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CYRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CYRXDie Einnahmen des Unternehmens (9.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: CYRXDie Einnahmen des Unternehmens (9.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CYRX wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y